Results 101 to 110 of about 165,269 (210)

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. [PDF]

, 2008
The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of ...
Aizenstein, Brian, Apsel, Beth, Blair, Jimmy A, Feldman, Morri E, Gonzalez, Beatriz, Hoffman, Randy, Knight, Zachary A, Nazif, Tamim M, Shokat, Kevan M, Williams, Roger L   +9 more
core  

Contemporary Drug-Eluting Stents and Vascular Response

European Medical Journal, 2017
Cardiovascular disease is a leading cause of death and disability worldwide. Current treatment strategies aimed at treating the consequences of coronary artery disease have embraced both optimal medical therapy and catheter based percutaneous coronary ...
Anwer Habib, Hiroyoshi Mori, Kazuyuki Yahagi, Aloke V. Finn   +3 more
doaj  

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. [PDF]

, 2016
In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus.
Campbell-Baird, Cynthia, Divers, Josephine, Elad, Sharon, Glaspy, John, Hronek, Jan, Meiller, Timothy F, O'Shaughnessy, Joyce A, Peterson, Douglas E, Rugo, Hope S, Schmidt, Brian L, Schubert, Mark M, Seery, Virginia, Viet, Chi T   +12 more
core  

Exogenous phosphatidylserine protects against mesenteric ischemia-reperfusion with associated Akt/mTOR pathway upregulation

Scientific Reports
Acute mesenteric ischemia–reperfusion is a life-threatening condition that causes severe intestinal injury through oxidative stress, inflammation, and apoptosis.
Amirabbas Mohammadi Hamaneh, Moein Ghasemi, Mohammad Mahdi Mehrabi, Sara Ashtari, Fatemeh Nejati, Houman Kazemzadeh, Ramin Goudarzi, Seyed Mohammad Tavangar, Ahmad Reza Dehpour, Alireza Partoazar   +9 more
doaj   +1 more source

Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study. [PDF]

Diagnostics (Basel)
Gebes M, Oral Tapan O, Edgunlu T, Dogan E.   +3 more
europepmc   +1 more source

Intravenous immunoglobulin and mammalian target of rapamycin inhibitors for treatment of BK virus infections in kidney transplantation: a systematic review. [PDF]

Clin Transplant Res
Fong KY, Kee T, Thangaraju S, Ho QY, Liew IT, Tien C, Aslim EJ, Ng LG, Lim EJ, Gan VHL.   +9 more
europepmc   +1 more source

The role of mammalian target of rapamycin inhibitors in mitigating cyclophosphamide-induced ovarian damage in a murine model. [PDF]

Clin Exp Reprod Med
Kim SK, Jee BC.
europepmc   +1 more source

Design, Synthesis, and Evaluation of Naphthyl Pyrazino-Pyrido-Pyrimidinones Targeting the Phosphoinositide 3-Kinase/Alpha-Serine/Protein Kinase B/Mammalian Target of Rapamycin Pathway. [PDF]

ChemistryOpen
Marchiori MF, da Silva G, Kawano DF, Leopoldino AM, Madruga E, Martinez A, Carvalho I.   +6 more
europepmc   +1 more source

Synergistic anti-hepatoma effect of triptolide and quercetin <i>via</i> co-inhibition and interaction with Janus kinase and mammalian target of rapamycin signal pathway. [PDF]

World J Gastroenterol
Tong HX, Zhang JL, Nie WY, Jiang LJ, Hu JQ, Lu T.   +5 more
europepmc   +1 more source

Mammalian target of rapamycin (mTOR) inhibitors in dermatology

Indian Journal of Dermatology, Venereology and Leprology, 2023
Anand, Mannu, Shekhar, Neema, Biju, Vasudevan, Siddharth, Bhatt   +3 more
openaire   +2 more sources